← Eichor
Condition: Hpv Mediated P16 Positive Oropharyngeal Carcinoma By Ajcc V8 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hpv Mediated P16 Positive Oropharyngeal Carcinoma By Ajcc V8

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · 153 location(s) · NRG Oncology · NCT06532279De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
Phase 2 · 3 location(s) · Mayo Clinic · NCT05541016BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer
Phase 2 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06323460Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Phase 1 · 18 location(s) · National Cancer Institute (NCI) · NCT05172245Oropharynx (OPX) Biomarker Trial
Phase N/A · 1 location(s) · Mayo Clinic · NCT06356272Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 · 100 location(s) · National Cancer Institute (NCI) · NCT07195734Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest
Phase 2 · 1 location(s) · Mayo Clinic · NCT06997068Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT07156227Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Can
Phase 2 · 2 location(s) · Northwestern University · NCT07178301TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous
Phase 1 · 2 location(s) · Emory University · NCT06868433Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radi
NA · 1 location(s) · Emory University · NCT06662058Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastati
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT03010150Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
Phase 2 · 2 location(s) · Jonathan Schoenfeld, MD, MPH · NCT04900623Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 · 2 location(s) · Emory University · NCT06636734Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascula
EARLY_Phase 1 · 1 location(s) · Emory University · NCT06914999
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.